


## PHARMACEUTICAL 2018

## Viking Therapeutics Inc. Rank 273 of 349





## PHARMACEUTICAL 2018

## Viking Therapeutics Inc. Rank 273 of 349

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 111% points. The greatest weakness of Viking Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 241% points.

The company's Economic Capital Ratio, given in the ranking table, is -447%, being 169% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	21,852
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,657
Liabilities, Non-Current	0
Other Assets	270
Other Compr. Net Income	-13
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,507
Property and Equipment	0
Research and Development	13,741
Revenues	0
Selling, General and Administrative Expense	5,329

Output Variable	Value in 1000 USD
Assets	22,121
Liabilities	8,657
Expenses	19,070
Stockholders Equity	13,465
Net Income	-20,578
Comprehensive Net Income	-20,584
Economic Capital Ratio	-447%